News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cytos Biotechnology AG Says Allergy Drug Meets Main Target In Study


7/31/2009 9:02:25 AM

Reuters - An allergy treatment from Swiss biotech company Cytos (CYTN.S) met its main target in a mid-stage trial, the group said on Friday, boosting its battered shares. Patients taking CYT003-QbG10 for allergic rhinoconjunctivitis in the Phase IIb study had significantly lower allergy symptoms and reported a better quality of life than those taking a placebo, Cytos said in a statement.

Read at Reuters
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES